ECE2018 Poster Presentations: Pituitary and Neuroendocrinology Pituitary - Clinical (101 abstracts)
Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
Mustafa Demirpence 1 , Aslı Guler 2 , Hamiyet Yilmaz 1 , Ahmet Sayin 3 , Yeliz Pekcevik 4 , Hakan Turkon 5 , Ayfer Colak 6 , Elif Merve Ari 6 , Behnaz Aslanipour 7 , Gokcen Unal Kocabas 8 & Mehmet Calan 8
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Tepecik Training and Research Hospital, Izmir, Turkey; 2Department of Family Physician, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey; 3Department of Cardiology, Izmir Tepecik Research and Training Hospital, Izmir, Turkey; 4Department of Radiology, Izmir Tepecik Training and Research Hospital, Izmir, Turkey; 5Department of Medical Biochemistry, Canakkale Onsekiz Mart University, Faculty of Medicine, Canakkale, Turkey; 6Department of Clinical Biochemistry, Izmir Tepecik Training and Research Hospital, Izmir, Turkey; 7Department of Bioengineering, Faculty of Engineering, Ege University, Izmir, Turkey; 8Division of Endocrinology and Metabolism, Department of Internal Medicine, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Purpose: Acromegaly, an uncommon disease, is existed in the result of over production of growth hormone (GH). It is associated with increased cardiovascular risk factors and metabolic abnormalities. Urotensin II (UII), a secreted vasoactive peptide hormone, plays an essential role in the regulation of vascular tone, glucose metabolism and atherosclerosis. UII belonging to somatostatin superfamily activates somatostatin receptors as well. The aim of this study was to ascertain whether circulating UII levels are altered in subjects with acromegaly and to describe the relationship between UII and hormonal or cardio-metabolic parameters.
Methods: This cross-sectional study included 41 subjects with active acromegaly, 28 subjects with controlled acromegaly and 37 age- and BMI-matched controls without acromegaly. Hormonal and metabolic features of the subjects as well as carotid intima media thickness (cIMT) and epicardial fat thickness (EFT) were defined. Circulation of UII levels was determined via ELISA.
Results: Both active and controlled acromegalic subjects showed a significant elevation of circulating levels of UII with respect to controls. There was no remarkable difference in circulating levels of UII between active and controlled acromegalic groups. Both cIMT and EFT were remarkably increased in acromegaly subjects comparing to controls. UII positively correlated with cIMT, EFT, BMI and HOMA-IR. There was no correlation between UII and GH, insulin-like growth factor-1. According to the results obtained from regression models, UII levels independently predicted cIMT and EFT.
Conclusion: Elevated UII levels are associated with severity of cardiovascular risk factors including cIMT and EFT in acromegalic subjects.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more